Mobile

A randomised, double-blind, placebo-controlled 4-period crossover study to assess the efficacy and safety of repeat dose intranasal GSK1004723 (1000μg), oral GSK835726 (10mg) and cetirizine (10mg) in ...

Mise à jour : Il y a 4 ans
Référence : EUCTR2009-011459-39

A randomised, double-blind, placebo-controlled 4-period crossover study to assess the efficacy and safety of repeat dose intranasal GSK1004723 (1000μg), oral GSK835726 (10mg) and cetirizine (10mg) in the environmental challenge chamber in subjects with seasonal allergic rhinitis

Femme et Homme

  • | Pays :
    • -
  • | Organes :
    • -
  • | Spécialités :
    • -

Extrait

Investigate the effect of repeat intranasal doses of GSK1004723 vs. placebo on prevention of nasal symptoms of allergic rhinitis provoked by allergen and assessed during 6 hours in the environmental challenge chamber (1h post-GSK1004723 dose). Investigate the effect of repeat oral doses of GSK835726 vs. placebo on prevention of nasal symptoms of allergic rhinitis provoked by allergen and assessed during 6 hours in the environmental challenge chamber (1h post-GSK835726 dose).

Critère d'inclusion

  • Seasonal Allergic Rhinitis

Liens